XLON
VAL
Market cap2mUSD
May 23, Last price
0.55GBP
1D
0.00%
1Q
-12.00%
Jan 2017
-99.92%
Name
ValiRx PLC
Chart & Performance
P/E
—
P/S
21,447.08
EPS
—
Div Yield, %
—
Shrs. gr., 5y
94.28%
Rev. gr., 5y
%
Revenues
10k
Net income
-2m
L-15.31%
CFO
-2m
L+3.51%
Earnings
Sep 25, 2025
Profile
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 10 | ||||||||
Cost of revenue | 2,307 | 2,278 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (2,298) | (2,278) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (175) | (193) | |||||||
Tax Rate | |||||||||
NOPAT | (2,123) | (2,085) | |||||||
Net income | (2,038) -15.31% | (2,406) 55.52% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,300 | 2,487 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 10 | 16 | |||||||
Long-term debt | 12 | 28 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (153) | (1,094) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (1,772) | (1,712) | |||||||
CAPEX | (291) | ||||||||
Cash from investing activities | (306) | ||||||||
Cash from financing activities | 1,116 | 2,256 | |||||||
FCF | (2,355) | (2,137) | |||||||
| Balance | |||||||||
Cash | 175 | 1,137 | |||||||
Long term investments | |||||||||
Excess cash | 174 | 1,137 | |||||||
Stockholders' equity | (24,967) | (24,186) | |||||||
Invested Capital | 27,893 | 28,033 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 101,570 | 77,302 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (2,044) | (2,066) | |||||||
EV/EBITDA | |||||||||
Interest | 4 | 5 | |||||||
Interest/NOPBT | |||||||||